<DOC>
	<DOCNO>NCT00031902</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining rituximab chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness rituximab plus combination chemotherapy treat patient HIV-related non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Plus Combination Chemotherapy Treating Patients With HIV-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient poor-prognosis , HIV-related non-Hodgkin 's lymphoma treat rituximab combine prednisolone , vincristine , bleomycin . - Determine toxicity regimen patient . - Determine time progression survival patient treat regimen . OUTLINE : This multicenter study . Patients receive chemotherapy comprise vincristine IV bleomycin IV day 1 oral prednisolone every day begin day 1 . Treatment repeat every 3 week 6 course . Patients also receive rituximab day 14 , 21 , 28 , 35 . Patients achieve complete response ( CR ) receive 2 additional course chemotherapy CR . Patients follow every 1-2 month . PROJECTED ACCRUAL : A total 10-20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis poorprognosis , HIVrelated nonHodgkin 's lymphoma ( HIVNHL ) Previously untreated More 1 follow criterion : Prior diagnosis AIDS ECOG performance status 34 CD4 count le 100/mm3 No primary cerebral lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy HIVNHL At least 1 year since prior chemotherapy Kaposi 's sarcoma ( KS ) Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy HIVNHL allow At least 1 year since prior radiotherapy KS Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
</DOC>